{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:44:10Z","timestamp":1771040650900,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.prp.2023.154517","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:20:26Z","timestamp":1683825626000},"page":"154517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML"],"prefix":"10.1016","volume":"246","author":[{"given":"Martina","family":"Murkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emina","family":"Babarovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bla\u017een","family":"Mariji\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Grohovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ita","family":"Had\u017eisejdi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154517_bib1","series-title":"Molecular Hematology: Third Edition","first-page":"76","article-title":"Chronic Myelogenous Leukemia","author":"Quint\u00e1s-Cardama","year":"2010"},{"issue":"3","key":"10.1016\/j.prp.2023.154517_bib2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"93","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.prp.2023.154517_bib3","series-title":"Lion","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised fourth ed.","author":"Swerdlow","year":"2017"},{"issue":"10","key":"10.1016\/j.prp.2023.154517_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.prp.2023.154517_bib5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"984\u2013966","key":"10.1016\/j.prp.2023.154517_bib6","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2023.154517_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fonc.2019.00863","article-title":"Assessing measurable residual disease in chronic myeloid leukemia. BCR-ABL1 IS in the avant-garde of molecular hematology","volume":"9","author":"Moisoiu","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2023.154517_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bjhh.2014.08.003","article-title":"Is the BCR-ABL\/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?","volume":"37","author":"Bonecker","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"2","key":"10.1016\/j.prp.2023.154517_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.prp.2023.154517_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic myelogenous leukemia, a still unsolved problem: Pitfalls and new therapeutic possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug. Des. Dev. Ther."},{"issue":"7","key":"10.1016\/j.prp.2023.154517_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1179\/1607845414Y.0000000221","article-title":"Bone marrow fibrosis may be an effective independent predictor of the \u2018TKI drug response level\u2019 in chronic myeloid leukemia","volume":"20","author":"Eliacik","year":"2015","journal-title":"Hematol"},{"issue":"8","key":"10.1016\/j.prp.2023.154517_bib12","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.prp.2023.154517_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1309\/AJCP2UG9SGGWAHUA","article-title":"Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia","volume":"136","author":"Koopmans","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.prp.2023.154517_bib14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1309\/AJCPT5Y2JRIUUCUB","article-title":"Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma","volume":"137","author":"Babarovi\u0107","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2023.154517_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/jir.1996.16.217","article-title":"Effect of interferon therapy on bone marrow morphology in chronic myeloid leukemia: a cytochemical and immunohistochemical study of trephine biopsies","volume":"16","author":"Thiele","year":"1996","journal-title":"J. Interferon Cytokine Res"},{"key":"10.1016\/j.prp.2023.154517_bib16","article-title":"Effect of imatinib on bone marrow morphology and angiogenesis in chronic myeloid leukemia","volume":"8","author":"Pandey","year":"2019","journal-title":"Adv. Hematol."},{"issue":"19","key":"10.1016\/j.prp.2023.154517_bib17","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1002\/cncr.31663","article-title":"Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: assessment of potential value","volume":"124","author":"Hidalgo-L\u03ccpez","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.prp.2023.154517_bib18","first-page":"1241","article-title":"Bone marrow histopathology in chronic myelogenous leukemia (CML)- Evaluation of distinctive features with clinical impact","volume":"14","author":"Thiele","year":"1999","journal-title":"Histol. Histopathol."},{"issue":"1","key":"10.1016\/j.prp.2023.154517_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2004.10.012","article-title":"Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia","volume":"36","author":"Lugli","year":"2005","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2023.154517_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5114\/pjp.2017.71532","article-title":"The significance of angiogenesis for predicting optimal therapeutic response in chronic myeloid leukaemia patients","volume":"68","author":"\u0106ojba\u0161i\u0107","year":"2017","journal-title":"Pol. J. Pathol."},{"issue":"22","key":"10.1016\/j.prp.2023.154517_bib21","first-page":"5830","article-title":"Overexpression of hypoxia-inducible factor 1\u03b1 in common human cancers and their metastases","volume":"59","author":"Zhong","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.prp.2023.154517_bib22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2023.154517_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.24293\/ijcpml.v26i2.1457","article-title":"Differences of bone marrow features and BCR-ABL variants in chronic granulocytic leukemia post tyrosine kinase inhibitor therapy","volume":"26","author":"Devi","year":"2020","journal-title":"Indones. J. Clin. Pathol. Med. Lab."},{"issue":"1","key":"10.1016\/j.prp.2023.154517_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/7531472","article-title":"The Hasford score may predict molecular response in chronic myeloid leukemia patients: a single institution experience","volume":"4","author":"Dybko","year":"2016","journal-title":"Dis. Markers"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:00:39Z","timestamp":1759734039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823002170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":24,"alternative-id":["S0344033823002170"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154517","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154517"}}